Anas Younes

Anas Younes

UNVERIFIED PROFILE

Are you Anas Younes?   Register this Author

Register author
Anas Younes

Anas Younes

Publications by authors named "Anas Younes"

Are you Anas Younes?   Register this Author

100Publications

-Reads

BET Inhibition-Induced GSK3β Feedback Enhances Lymphoma Vulnerability to PI3K Inhibitors.

Cell Rep 2018 Aug;24(8):2155-2166

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address:

View Article
August 2018

Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.

J Clin Oncol 2018 May 27;36(14):1428-1439. Epub 2018 Mar 27.

Philippe Armand and Margaret A. Shipp, Dana-Farber Cancer Institute, Boston, MA; Andreas Engert, University Hospital of Cologne, Cologne, Germany; Anas Younes, Memorial Sloan Kettering Cancer Center, New York, NY; Michelle Fanale, University of Texas MD Anderson Cancer Center, Houston, TX; Armando Santoro, Humanitas Cancer Center, Humanitas University, Milan; Pier Luigi Zinzani, Institute of Hematology "L. e A. Seràgnoli," University of Bologna, Bologna, Italy; John M. Timmerman, University of California Los Angeles Medical Center, Los Angeles, CA; Graham P. Collins, Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford, United Kingdom; Radhakrishnan Ramchandren, Barbara Ann Karmanos Cancer Institute, Detroit, MI; Jonathon B. Cohen, Winship Cancer Institute, Emory University, Atlanta, GA; Jan Paul De Boer, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands, on behalf of Lunenburg Lymphoma Phase I/II Consortium; John Kuruvilla, University of Toronto and Princess Margaret Cancer Centre, Toronto, Ontario; Kerry J. Savage, BC Cancer Agency, Vancouver, British Columbia, Canada; Marek Trneny, Charles University, General Hospital in Prague, Prague, Czech Republic; Kazunobu Kato, Anne Sumbul, and Benedetto Farsaci, Bristol-Myers Squibb, Princeton, NJ; and Stephen M. Ansell, Mayo Clinic, Rochester, MN.

View Article
May 2018

Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.

J Clin Oncol 2018 Apr 2;36(10):942-950. Epub 2018 Feb 2.

Margaretha G.M. Roemer, Robert A. Redd, Fathima Zumla Cader, Christine J. Pak, Sara Abdelrahman, Jing Ouyang, Philippe Armand, Donna S. Neuberg, and Margaret A. Shipp, Dana-Farber Cancer Institute; Geraldine S. Pinkus, Azra H. Ligon, and Scott J. Rodig, Brigham and Women's Hospital, Boston, MA; Margaretha G.M. Roemer, VU University Medical Center; Jan Paul De Boer, Antoni van Leeuwenhoek Hospital, Lunenburg Phase I/II Consortium, Amsterdam, the Netherlands; Stephanie Sasse, University Hospital of Cologne, Cologne, Germany; Anas Younes, Memorial Sloan Kettering Cancer Center, New York, NY; Michelle Fanale, University of Texas MD Anderson Cancer Center, Houston, TX; Armando Santoro, Humanitas University, Rozzano, Milan; Pier Luigi Zinzani, University of Bologna, Bologna, Italy; John Timmerman, University of California, Los Angeles Medical Center, Los Angeles, CA; Graham P. Collins, Churchill Hospital, Oxford, United Kingdom; Radhakrishnan Ramchandren, Barbara Ann Karmanos Cancer Institute, Detroit, MI; Jonathon B. Cohen, Emory University, Atlanta, GA; John Kuruvilla, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Kerry J. Savage, British Columbia Cancer Agency Center for Lymphoid Cancer, Vancouver, British Columbia, Canada; Marek Trneny, Charles University in Prague, General University Hospital in Prague, Prague, Czech Republic; Stephen Ansell, Mayo Clinic, Rochester, MN; and Kazunobu Kato, Benedetto Farsaci, and Anne Sumbul, Bristol-Myers Squibb, Princeton, NJ.

View Article
April 2018

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.

N Engl J Med 2018 01 10;378(4):331-344. Epub 2017 Dec 10.

From the University of British Columbia and the Department of Medical Oncology, British Columbia Cancer Agency Centre for Lymphoid Cancer, Vancouver, Canada (J.M.C., K.J.S.); the Department of Hematology, Jagiellonian University, Krakow (W.J.), the Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw (E.L.-M.), the Department of Hematology and Transfusion Medicine, Center of Postgraduate Medical Education, Warsaw (E.L.-M.), the Department of Experimental Hematology, Medical University of Lodz, Lodz (P.S.), and the Department of Lymphoid Malignancy, the Maria Sklodowska-Curie Memorial Institute and Oncology Center, Warsaw (J.W.) - all in Poland; Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York (D.J.S., A.Y.); the Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN (S.M.A.); the Division of Hematology and Oncology, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea (W.S.K.); Research Innovation and Statistics, Antoine-Lacassagne Cancer Center, Nice, France (A.G.); Petrov Research Institute of Oncology, St. Petersburg, Russia (S.A.); the Department of Hematology, Faculty of Medicine, University of Debrecen, Debrecen (Á.I.), and the Department of Hematology, National Institute of Oncology, Budapest (A.R.) - both in Hungary; the Department of Advanced Biomedical Science, Federico II University Hospital, Naples (M.P.), and the Institute of Hematology Seràgnoli, University of Bologna, Bologna (P.L.Z.) - both in Italy; the Department of Lymphoma and Myeloma, M.D. Anderson Cancer Center, Houston (Y.O.); John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ (T.F.); the Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis (N.L.B.); the Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA (R.C.); the Department of Hematology-Oncology, Barbara Ann Karmanos Cancer Center, Detroit (R.R.); Gastrointestinal and Lymphoma Unit, The Royal Marsden NHS Foundation Trust, Sutton (D.C.), and the Department of Medical Oncology, University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester (J.R.) - both in the United Kingdom; the Department of Clinical Development, Seattle Genetics, Bothell, WA (N.C.J., E.S.); and Oncology Clinical Research (J.S., H.A.J., D.H.) and Global Biostatistics (R.L.), Millennium Pharmaceuticals, Cambridge, MA.

View Article
January 2018

Authors' Reply.

J Mol Diagn 2018 Jan;20(1):125-126

Interpretation of Sequence Variants in Somatic Conditions Working Group of the Clinical Practice Committee, Association for Molecular Pathology, Bethesda, Maryland; University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.

View Article
January 2018

Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma.

Blood 2017 09 21;130(11):1375-1377. Epub 2017 Jul 21.

Memorial Sloan Kettering Cancer Center, New York, NY.

View Article
September 2017

The landscape of new drugs in lymphoma.

Nat Rev Clin Oncol 2017 Jun 29;14(6):335-346. Epub 2016 Dec 29.

UNMC Oncology/Haematology Division, 987680 Nebraska Medical Center, Omaha, Nebraska 681980-7680, USA.

View Article
June 2017

Ibrutinib in PCNSL: The Curious Cases of Clinical Responses and Aspergillosis.

Cancer Cell 2017 06 25;31(6):731-733. Epub 2017 May 25.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address:

View Article
June 2017

Clinical applications of genome studies.

Authors:
Anas Younes

Hematol Oncol 2017 Jun;35 Suppl 1:67-69

Memorial Sloan Kettering Cancer Center, New York, NY, USA.

View Article
June 2017

Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations.

J Natl Cancer Inst 2017 04 31;109(4). Epub 2016 Dec 31.

Affiliations of authors: NYU Perlmutter Cancer Center, New York, NY (CSD); BC Cancer Agency Centre for Lymphoid Cancer, Vancouver, BC, Canada (JMC); Wilmot Cancer Center and Division of Hematology/Oncology, University of Rochester Medical Center, Rochester, NY (JWF); Department of Medicine, Weil Cornell University, New York, NY (JPL); Oncology Division, Department of Medicine, Washington University, St. Louis, MO (BSK, NLB); Division of Cancer Treatment and Diagnosis (RFL) and Coordinating Center for Clinical Trials (LB), Tufts Cancer Center and Division of Hematology/Oncology, Tufts University School of Medicine, Boston, MA (AME); Stanford Cancer Institute, Stanford University Medical School, Stanford, CA (RTH); Division of Pediatric Hematology/Oncology/Stem Cell Transplant, Columbia University Medical Center, New York, NY (KMK); Department of Medicine, University of Arizona Cancer Center, Tucson, AZ (DOP); Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY (AY); Department of Radiology, Mount Sinai Hospital, New York, NY (LK).

View Article
April 2017

High grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6: Double hit and triple hit lymphomas and double expressing lymphoma.

Blood Rev 2017 Mar 30;31(2):37-42. Epub 2016 Sep 30.

Memorial Sloan Kettering Cancer Center New York City, NY, USA.

View Article
March 2017

Clinical Trials in the Genomic Era.

J Clin Oncol 2017 Mar 13;35(9):1011-1017. Epub 2017 Feb 13.

All authors: Memorial Sloan Kettering Cancer Center, New York, NY.

View Article
March 2017

Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists.

J Mol Diagn 2017 01;19(1):4-23

Interpretation of Sequence Variants in Somatic Conditions Working Group of the Clinical Practice Committee, Association for Molecular Pathology, Bethesda, Maryland; University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.

View Article
January 2017

ACR Appropriateness Criteria® Hodgkin Lymphoma-Favorable Prognosis Stage I and II.

Am J Clin Oncol 2016 12;39(6):535-544

*University of Rochester Medical Center, Rochester †††Memorial Sloan Kettering Cancer Center, American Society of Clinical Oncology, New York, NY †Stanford Cancer Center, American Society of Clinical Oncology, Stanford ‡University of Southern California Keck School of Medicine, Los Angeles, CA §University of Texas MD Anderson Cancer Center, Houston ¶University of Texas Health Science Center at San Antonio, San Antonio, TX ∥Emory University, American Society of Clinical Oncology, Atlanta, GA #University of Florida Proton Therapy Institute, Jacksonville **University of Florida, Gainesville, FL ††St. Jude Children's Research Hospital, American Society of Clinical Oncology, Memphis, TN ‡‡University of Pennsylvania Health System, Philadelphia, PA §§Yale University School of Medicine, New Haven, CT ∥∥Richard L. Roudebush VA Medical Center, Indiana University School of Medicine, Indianapolis, IN ¶¶The University of Chicago, American Society of Hematology, Chicago, IL ##Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, Baltimore, MD ***Massachusetts General Hospital, Boston, MA.

View Article
December 2016

Promising Novel Agents for Aggressive B-Cell Lymphoma.

Authors:
Anas Younes

Hematol Oncol Clin North Am 2016 Dec;30(6):1229-1237

Lymphoma Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA. Electronic address:

View Article
December 2016

Targeting CD30 Using Brentuximab Vedotin in the Treatment of Hodgkin Lymphoma.

Cancer J 2016 Jan-Feb;22(1):23-6

From the Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article
November 2016

ACR Appropriateness Criteria® Hodgkin Lymphoma-Unfavorable Clinical Stage I and II.

Am J Clin Oncol 2016 08;39(4):384-95

*Yale University School of Medicine, New Haven, CT †Memorial Sloan Kettering Cancer Center, New York, American Society of Clinical Oncology ¶University of Rochester Medical Center, Rochester, NY ‡Princess Margaret Hospital, Toronto, ON, Canada §Stanford Cancer Center, Stanford, CA, American Society of Clinical Oncology ∥University of Texas MD Anderson Cancer Center, Houston **University of Texas Health Science Center at San Antonio, San Antonio, TX #Emory University, Atlanta, GA, American Society of Clinical Oncology ††University of Florida Proton Therapy Institute, Jacksonville ‡‡University of Florida, Gainesville, FL §§St Jude Children's Research Hospital, Memphis, TN, American Society of Clinical Oncology ∥∥University of Pennsylvania Health System, Philadelphia, PA ¶¶Richard L. Roudebush VA Medical Center, Indiana University School of Medicine, Indianapolis, IN ##The University of Chicago, Chicago, IL, American Society of Hematology ***Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, Baltimore, MD †††Massachusetts General Hospital, Boston, MA.

View Article
August 2016

The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints.

Haematologica 2016 07;101(7):794-802

Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA

View Article
July 2016

Novel agents in the treatment of Hodgkin lymphoma: Biological basis and clinical results.

Semin Hematol 2016 Jul 13;53(3):186-9. Epub 2016 May 13.

Mayo Clinic, Rochester, MN. Electronic address:

View Article
July 2016

Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.

Curr Treat Options Oncol 2016 06;17(6):31

Lymphoma Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 330, New York, NY, 10065, USA.

View Article
June 2016

Targeting Programmed Death 1/Programmed Death Ligand 1 in Lymphoma: A Game Changer.

Authors:
Anas Younes

J Oncol Pract 2016 Feb;12(2):107-8

Memorial Sloan Kettering Cancer Center, New York, NY

View Article
February 2016

Novel immunotherapies in lymphoid malignancies.

Nat Rev Clin Oncol 2016 Jan 3;13(1):25-40. Epub 2015 Nov 3.

Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 330, New York, NY 10065, USA.

View Article
January 2016

ACR Appropriateness Criteria® Diffuse Large B-Cell Lymphoma.

Am J Clin Oncol 2015 Dec;38(6):610-20

*University of Texas MD Anderson Cancer Center, Houston, TX †American Society of Clinical Oncology, Stanford Cancer Center, Stanford, CA ‡Princess Margaret Hospital, Toronto, Ontario, Canada §University of Rochester Medical Center ‡‡‡University of Rochester Medical Center, Rochester †††American Society of Clinical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY ∥American Society of Clinical Oncology, Emory University, Atlanta, GA ¶Univeristy of Texas Health Science Center at San Antonio, San Antonio, TX #University of Florida Proton Therapy Institute, Jacksonville **University of Florida, Gainesville, FL ††American Society of Clinical Oncology, St. Jude Children's Research Hospital, Memphis, TN ‡‡University of Pennsylvania Health System, Philadelphia, PA §§Yale University School of Medicine, New Haven, CT ∥∥Richard L. Roudebush VA Medical Center, Indiana University School of Medicine, Indianapolis, IN ¶¶American Society of Hematology, University of Chicago, Chicago, IL ##Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, Baltimore, MD ***Massachusetts General Hospital, Boston, MA.

View Article
December 2015

Antibody-drug conjugates in hematologic malignancies.

Am Soc Clin Oncol Educ Book 2013

From the Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX; Lymphoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY.

View Article
November 2015

Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma.

Br J Haematol 2015 Nov 27;171(4):463-70. Epub 2015 Jul 27.

Department of Lymphoma/Myeloma, The University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA.

View Article
November 2015

Lymphomagenesis in Hodgkin lymphoma.

Semin Cancer Biol 2015 Oct 25;34:14-21. Epub 2015 Feb 25.

Lymphoma Service, Memorial Sloan-Kettering Cancer Center, United States. Electronic address:

View Article
October 2015

Lymphomas and microenvironment: Impact on lymphomagenesis. Foreword.

Semin Cancer Biol 2015 Oct 28;34:1-2. Epub 2015 May 28.

Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

View Article
October 2015

Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin: Seeing the Forest and the Trees.

Authors:
Anas Younes

J Clin Oncol 2015 Sep 10;33(26):2835-6. Epub 2015 Aug 10.

Memorial Sloan Kettering Cancer Center, New York, NY

View Article
September 2015

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.

Authors:
Ayalew Tefferi Hagop Kantarjian S Vincent Rajkumar Lawrence H Baker Jan L Abkowitz John W Adamson Ranjana Hira Advani James Allison Karen H Antman Robert C Bast John M Bennett Edward J Benz Nancy Berliner Joseph Bertino Ravi Bhatia Smita Bhatia Deepa Bhojwani Charles D Blanke Clara D Bloomfield Linda Bosserman Hal E Broxmeyer John C Byrd Fernando Cabanillas George Peter Canellos Bruce A Chabner Asher Chanan-Khan Bruce Cheson Bayard Clarkson Susan L Cohn Gerardo Colon-Otero Jorge Cortes Steven Coutre Massimo Cristofanilli Walter J Curran George Q Daley Daniel J DeAngelo H Joachim Deeg Lawrence H Einhorn Harry P Erba Francisco J Esteva Elihu Estey Isaiah J Fidler James Foran Stephen Forman Emil Freireich Charles Fuchs James N George Morie A Gertz Sergio Giralt Harvey Golomb Peter Greenberg Jordan Gutterman Robert I Handin Samuel Hellman Paulo Marcelo Hoff Ronald Hoffman Waun Ki Hong Mary Horowitz Gabriel N Hortobagyi Clifford Hudis Jean Pierre Issa Bruce Evan Johnson Philip W Kantoff Kenneth Kaushansky David Khayat Fadlo R Khuri Thomas J Kipps Margaret Kripke Robert A Kyle Richard A Larson Theodore S Lawrence Ross Levine Michael P Link Scott M Lippman Sagar Lonial Gary H Lyman Maurie Markman John Mendelsohn Neal J Meropol Yoav Messinger Therese M Mulvey Susan O'Brien Roman Perez-Soler Raphael Pollock Josef Prchal Oliver Press Jerald Radich Kanti Rai Saul A Rosenberg Jacob M Rowe Hope Rugo Carolyn D Runowicz Brenda M Sandmaier Alan Saven Andrew I Schafer Charles Schiffer Mikkael A Sekeres Richard T Silver Lillian L Siu David P Steensma F Marc Stewart Wendy Stock Richard Stone Rainer Storb Louise C Strong Martin S Tallman Michael Thompson Naoto T Ueno Richard A Van Etten Julie M Vose Peter H Wiernik Eric P Winer Anas Younes Andrew D Zelenetz Charles A LeMaistre

Mayo Clin Proc 2015 Aug 23;90(8):996-1000. Epub 2015 Jul 23.

View Article
August 2015

Precision medicine in diffuse large B-cell lymphoma: hitting the target.

Haematologica 2015 Aug;100(8):989-93

Department of Haematology, Academic Medical Center, Amsterdam, The Netherlands

View Article
August 2015

Experience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin lymphoma.

Haematologica 2015 Jul 27;100(7):e272-4. Epub 2015 Mar 27.

Department of Lymphoma and Myeloma, University of Texas, MD Anderson Cancer Center, Houston, TX 77030 USA.

View Article
July 2015

Detection of classical Hodgkin lymphoma specific sequence in peripheral blood using a next-generation sequencing approach.

Br J Haematol 2015 Jun 29;169(5):689-93. Epub 2015 Mar 29.

Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.

View Article
June 2015

XII. Therapeutic exploitation of autologous T-cell activation in B-cell lymphoma.

Authors:
Anas Younes

Hematol Oncol 2015 Jun;33 Suppl 1:67-9

Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, 10065, NY, USA.

View Article
June 2015

FDG PET/CT imaging as a biomarker in lymphoma.

Eur J Nucl Med Mol Imaging 2015 Apr 9;42(4):623-33. Epub 2015 Jan 9.

LYSA Imaging, Department of Nuclear Medicine, Hôpitaux Universitaires Henri Mondor, Paris-Est Créteil University, Créteil, 94010, France,

View Article
April 2015

Emerging drugs for diffuse large B-cell lymphoma.

Expert Rev Anticancer Ther 2015 Apr 5;15(4):439-51. Epub 2015 Feb 5.

Department of Human Pathology, University of Messina, Via C. Valeria, 98100 Messina, Italy.

View Article
April 2015

Novel targeted therapies in diffuse large B-cell lymphoma.

Semin Hematol 2015 Apr 19;52(2):126-37. Epub 2015 Jan 19.

Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, NY. Electronic address:

View Article
April 2015

A phase 1 dose-escalation study of XmAb® 2513 in patients with relapsed or refractory Hodgkin lymphoma.

Br J Haematol 2015 Mar 1;168(6):902-4. Epub 2014 Oct 1.

Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

View Article
March 2015

Precision therapy for lymphoma--current state and future directions.

Nat Rev Clin Oncol 2014 Oct 19;11(10):585-96. Epub 2014 Aug 19.

Lymphoma Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 330, New York, NY 10065, USA.

View Article
October 2014

Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy.

Ann Hematol 2014 Aug 29;93(8):1263-77. Epub 2014 May 29.

Department of Pathology, Centro di Riferimento Oncologico (CRO) Aviano, Istituto Nazionale Tumori, IRCCS, Via F. Gallini 2, 33081, Aviano, Italy,

View Article
August 2014

Novel therapy for Hodgkin lymphoma.

Hematology Am Soc Hematol Educ Program 2013 ;2013:394-9

1Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, NY.

View Article
July 2014

Role of CD30 targeting in malignant lymphoma.

Curr Treat Options Oncol 2014 Jun;15(2):210-25

Lymphoma Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Box 330, New York, NY, 10065, USA.

View Article
June 2014

Diffuse large B-cell lymphoma: changing treatment paradigms.

Oncology (Williston Park) 2014 Apr;28(4):339-41

View Article
April 2014

From empiric to mechanism-based therapy for peripheral T cell lymphoma.

Int J Hematol 2014 Mar 8;99(3):249-62. Epub 2014 Feb 8.

Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 330, New York, NY, 10065, USA.

View Article
March 2014

Brentuximab vedotin for the treatment of patients with Hodgkin lymphoma.

Authors:
Anas Younes

Hematol Oncol Clin North Am 2014 Feb;28(1):27-32

Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA. Electronic address:

View Article
February 2014

A novel immunomodulatory molecularly targeted strategy for refractory Hodgkin's lymphoma.

Oncotarget 2014 Jan;5(1):95-102

Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article
January 2014

Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma.

Clin Cancer Res 2013 Dec 4;19(24):6882-90. Epub 2013 Oct 4.

Authors' Affiliations: Departments of Lymphoma/Myeloma, Diagnostic Imaging, and Biostatistics, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas.

View Article
December 2013

In the spotlight: a novel CD37 antibody-drug conjugate.

Blood 2013 Nov;122(20):3397-8

MEMORIAL SLOAN-KETTERING CANCER CENTER.

View Article
November 2013

Brentuximab vedotin: the science of common sense.

Leuk Lymphoma 2013 Oct 30;54(10):2089-90. Epub 2013 Apr 30.

Memorial Sloan-Kettering Cancer Center , New York, NY , USA.

View Article
October 2013

XIV. The rationale for combining targeted and biological anti-lymphoma drugs.

Authors:
Anas Younes

Hematol Oncol 2013 Jun;31 Suppl 1:81-3

Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

View Article
June 2013

Antibody-drug conjugate technology development for hematologic disorders.

Clin Adv Hematol Oncol 2012 Aug;10(8 Suppl 10):1-16

Weill Medical College/Cornell University, New York-Presbyterian Hospital and Memorial Sloan-Kettering Cancer Center, New York, New York, USA.

View Article
August 2012